Trial reportPloS one2015
Randomized trial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans.
Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01682694 (Glucosamine and Chondroitin Effects), which is not on this map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Glucosamine and Chondroitin Effects
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- The Safety and Efficacy of Glucosamine and/or Chondroitin in Humans: A Systematic Review.Nutrients · 2025Pooled it
- Strategies to decrease oxidative stress biomarker levels in human medical conditions: A meta-analysis on 8-iso-prostaglandin FRedox biology · 2018Pooled it
- Trial
- Exploratory plasma proteomic analysis in a randomized crossover trial of aspirin among healthy men and women.PloS one · 2017Trial
- Nutritional Interventions in Osteoarthritis: Mechanisms, Clinical Evidence, and Translational Opportunities.Nutrients · 2026Review
- Glucosamine Use and Its Association with Colorectal Cancer and Mortality: A Systematic Review and Meta-Analysis.Journal of Cancer · 2026Article
- Association between glucosamine use and albuminuria in the UK: a cohort and Mendelian randomisation study.BMJ open · 2025Article
- Dietary glucosamine supplement use and lower surgery risk in individuals with inflammatory bowel disease: a prospective Cohort Study.European journal of nutrition · 2025Article
- A proposed framework for practical multimodal management of osteoarthritis in growing dogs.Frontiers in veterinary science · 2025Review
- Caloric restriction mimetics improve gut microbiota: a promising neurotherapeutics approach for managing age-related neurodegenerative disorders.Biogerontology · 2024Review
- Predictors of Psychiatric Complications in Patients with Pancreatic Cancer: A Retrospective Cohort Study.Actas espanolas de psiquiatria · 2024Article
- Causality of genetically determined glucosamine supplementation on cognition and sarcopenia: a Mendelian randomization study.Frontiers in endocrinology · 2024Article
- Article
- Glucosamine and Chondroitin Use and Mortality Among Adults in the United States from 1999 to 2014.Journal of integrative and complementary medicine · 2023Article
- Glucosamine use, smoking and risk of incident chronic obstructive pulmonary disease: a large prospective cohort study.The British journal of nutrition · 2022Article
- N-Palmitoyl-D-Glucosamine Inhibits TLR-4/NLRP3 and Improves DNBS-Induced Colon Inflammation through a PPAR-α-Dependent Mechanism.Biomolecules · 2022Article
- Heterologous production of chondroitin.Biotechnology reports (Amsterdam, Netherlands) · 2022Review
- Glucosamine Use and Risk of Colorectal Cancer: Results from UK Biobank.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- Risk of ischaemic stroke among new users of glucosamine and chondroitin sulphate: a nested case-control study.Therapeutic advances in musculoskeletal disease · 2022Article
- It's all in the milk: chondroitin sulfate as potential preventative therapy for necrotizing enterocolitis.Pediatric research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundGlucosamine and chondroitin are popular non-vitamin dietary supplements used for osteoarthritis. Long-term use is associated with lower incidence of colorectal and lung cancers and with lower mortality; however, the mechanism underlying these observations is unknown. In vitro and animal studies show that glucosamine and chondroitin inhibit NF-kB, a central mediator of inflammation, but no definitive trials have been done in healthy humans.
methodsWe conducted a randomized, double-blind, placebo-controlled, cross-over study to assess the effects of glucosamine hydrochloride (1500 mg/d) plus chondroitin sulfate (1200 mg/d) for 28 days compared to placebo in 18 (9 men, 9 women) healthy, overweight (body mass index 25.0-32.5 kg/m2) adults, aged 20-55 y. We examined 4 serum inflammatory biomarkers: C-reactive protein (CRP), interleukin 6, and soluble tumor necrosis factor receptors I and II; a urinary inflammation biomarker: prostaglandin E2-metabolite; and a urinary oxidative stress biomarker: F2-isoprostane. Plasma proteomics on an antibody array was performed to explore other pathways modulated by glucosamine and chondroitin.
resultsSerum CRP concentrations were 23% lower after glucosamine and chondroitin compared to placebo (P = 0.048). There were no significant differences in other biomarkers. In the proteomics analyses, several pathways were significantly different between the interventions after Bonferroni correction, the most significant being a reduction in the "cytokine activity" pathway (P = 2.6 x 10-16), after glucosamine and chondroitin compared to placebo.
conclusionGlucosamine and chondroitin supplementation may lower systemic inflammation and alter other pathways in healthy, overweight individuals. This study adds evidence for potential mechanisms supporting epidemiologic findings that glucosamine and chondroitin are associated with reduced risk of lung and colorectal cancer.
trial registrationClinicalTrials.gov NCT01682694.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.